Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Zynex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZYXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ZYXI's weekly volatility (10%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 17.7% over the past year.
Return vs Market: ZYXI exceeded the US Market which returned 20.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Zynex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall StShould You Investigate Zynex, Inc. (NASDAQ:ZYXI) At US$13.62?
2 weeks ago | Simply Wall StAre Insiders Selling Zynex, Inc. (NASDAQ:ZYXI) Stock?
1 month ago | Simply Wall StEarnings Miss: Zynex, Inc. Missed EPS By 23% And Analysts Are Revising Their Forecasts
Is Zynex undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZYXI ($13.87) is trading below our estimate of fair value ($20.56)
Significantly Below Fair Value: ZYXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZYXI is good value based on its PE Ratio (45.2x) compared to the US Medical Equipment industry average (48.8x).
PE vs Market: ZYXI is poor value based on its PE Ratio (45.2x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: ZYXI is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: ZYXI is overvalued based on its PB Ratio (8.9x) compared to the US Medical Equipment industry average (4.4x).
How is Zynex forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZYXI's forecast earnings growth (55.2% per year) is above the savings rate (2.2%).
Earnings vs Market: ZYXI's earnings (55.2% per year) are forecast to grow faster than the US market (22% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ZYXI's revenue (45% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: ZYXI's revenue (45% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ZYXI's Return on Equity is forecast to be high in 3 years time
How has Zynex performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZYXI has a high level of non-cash earnings.
Growing Profit Margin: ZYXI's current net profit margins (14.9%) are lower than last year (22.5%).
Past Earnings Growth Analysis
Earnings Trend: ZYXI has become profitable over the past 5 years, growing earnings by 49.4% per year.
Accelerating Growth: ZYXI's earnings growth over the past year (11.6%) is below its 5-year average (49.4% per year).
Earnings vs Industry: ZYXI earnings growth over the past year (11.6%) exceeded the Medical Equipment industry 0.2%.
Return on Equity
High ROE: ZYXI's Return on Equity (18.9%) is considered low.
How is Zynex's financial position?
Financial Position Analysis
Short Term Liabilities: ZYXI's short term assets ($57.6M) exceed its short term liabilities ($7.3M).
Long Term Liabilities: ZYXI's short term assets ($57.6M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: ZYXI is debt free.
Reducing Debt: ZYXI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Debt Coverage: ZYXI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ZYXI has no debt, therefore coverage of interest payments is not a concern.
What is Zynex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZYXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZYXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZYXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZYXI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZYXI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Thomas Sandgaard (61 yo)
Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD526.53K) is below average for companies of similar size in the US market ($USD1.79M).
Compensation vs Earnings: Thomas's compensation has been consistent with company performance over the past year.
|Chief Financial Officer||3.42yrs||US$727.78k||0.069% |
|Chief Operating Officer||1.33yrs||US$1.99m||0.015% |
|Director of Communications & Organizational Development||no data||no data||no data|
|Vice President of Sales||0.67yr||no data||no data|
|Director of Human Resources||no data||no data||no data|
|President & COO of Zynex Monitoring Solutions||no data||no data||no data|
|Information Systems Manager||no data||US$92.00k||no data|
Experienced Management: ZYXI's management team is considered experienced (2.4 years average tenure).
|Independent Director||2.83yrs||US$50.00k||0.067% |
|Independent Director||2.83yrs||US$40.00k||0.067% |
|Independent Director||2.67yrs||US$40.00k||0.072% |
Experienced Board: ZYXI's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.
Zynex, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Zynex, Inc.
- Ticker: ZYXI
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$481.858m
- Shares outstanding: 34.74m
- Website: https://www.zynex.com
Number of Employees
- Zynex, Inc.
- 9555 Maroon Circle
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ZYXI||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2004|
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stim...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/29 00:22|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.